LEHIGH
VALLEY, Pa. and AMES,
Iowa, Oct. 25, 2021 /PRNewswire/ -- Air Products
(NYSE: APD), a global leader in industrial gases and cryogenic
technology, and Sublime Stericeuticals Corporation, a process
design and equipment manufacturer serving the pharmaceutical
industry, today announced plans to collaborate and develop a
proprietary sublimation and desorption technology for a continuous
freeze-drying system for vaccine and drug solutions. Under a joint
development agreement (JDA), Air Products' proprietary cryogen
delivery and liquid nitrogen spray freezing technology will be used
in combination with Sublime's process design to spray crystallize
vaccine and drug solutions in a continuous sterile lyophilization
freeze drying environment.
"The development of a continuous solution for pharmaceutical
manufacturers fits well with our commitment to help our customers
improve productivity and quality across product applications. We
anticipate that the product resulting from this JDA will allow
pharmaceutical manufacturers to rapidly produce and preserve
high-value materials without compromising on yield or viability,"
said Francesco Maione, president,
Americas at Air Products. "This solution could also introduce a
process flow that allows larger manufacturers to be more agile and
establish more production options."
Freeze-drying, or lyophilization, is regularly used to preserve
biological products such as vaccines and
antihemophilic proteins. It is also used to stabilize
biopharmaceuticals, active pharmaceutical ingredients, and cell
extracts. Solutions containing the ingredients are freeze-dried
inside vials, and later reconstituted. Common quality-related
process issues today often greatly affect the final yield and cost
to produce these products.
"With this collaboration we plan to address the challenges that
pharmaceutical manufacturers have with long lyophilization
processing times, coupled with less than certain process outcomes.
It's the culmination of years of research and first-hand industry
experience. Our collaboration with Air Products will be key to
completing a successful commercialized development," said
Shawn Stimson, vice president of
Process Development for Sublime.
About Air Products
Air Products (NYSE:APD) is a
world-leading industrial gases company in operation for 80 years.
Focused on serving energy, environment and emerging markets, the
Company provides essential industrial gases, related equipment and
applications expertise to customers in dozens of industries,
including refining, chemical, metals, electronics, manufacturing,
and food and beverage. Air Products is also the global leader in
the supply of liquefied natural gas process technology and
equipment. The Company develops, engineers, builds, owns and
operates some of the world's largest industrial gas projects,
including: gasification projects that sustainably convert abundant
natural resources into syngas for the production of high-value
power, fuels and chemicals; carbon capture projects; and
world-scale carbon-free hydrogen projects supporting global
transportation and the energy transition.
The Company had fiscal 2020 sales of $8.9
billion from operations in 50 countries and has a current
market capitalization of approximately $65
billion. More than 19,000 passionate, talented and committed
employees from diverse backgrounds are driven by Air Products'
higher purpose to create innovative solutions that benefit the
environment, enhance sustainability and address the challenges
facing customers, communities, and the world. For more information,
visit airproducts.com or follow us on
LinkedIn Twitter, Facebook or Instagram.
About Sublime
Sublime is a process design and
equipment manufacturer serving the pharmaceutical industry with
extensive experience in FDA regulated sterile drug manufacturing
and product quality. For more information,
visit www.sublimestericeuticals.com
Cautionary Note Regarding Forward-Looking Statements: This
release contains "forward-looking statements" within the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are based on
management's expectations and assumptions as of the date of this
release and are not guarantees of future performance. While
forward-looking statements are made in good faith and based on
assumptions, expectations and projections that management believes
are reasonable based on currently available information, actual
performance and financial results may differ materially from
projections and estimates expressed in the forward-looking
statements because of many factors, including risk factors
described in our Annual Report on Form 10-K for the fiscal year
ended September 30, 2020. Except
as required by law, we disclaim any obligation or undertaking to
update or revise any forward-looking statements contained herein to
reflect any change in the assumptions, beliefs or expectations or
any change in events, conditions or circumstances upon which any
such forward-looking statements are based.
View original
content:https://www.prnewswire.com/news-releases/air-products-and-sublime-stericeuticals-announce-joint-agreement-to-develop-continuous-freeze-drying-equipment-for-vaccine-and-pharmaceutical-industries-301407598.html
SOURCE Air Products